Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K+-ATPase activity defects

R. Bianchi, C. Triban, P. Marini, B. Figliomeni, M. Paro, G. Italiano, M. Prosdocimi, M. G. Fiori

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Bovine brain gangliosides have been shown to prevent decay in Na+,K+-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K+-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39% decrease in Na+,K+-ATPase activity of the vagus nerve, which was completely restored (96-97% recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy.

Original languageEnglish
Pages (from-to)107-111
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume12
Issue number2
DOIs
Publication statusPublished - 1991

Fingerprint

Autonomic Pathways
Alloxan
Gangliosides
Esters
Vagus Nerve
Diabetic Neuropathies
Sciatic Nerve
Streptozocin
Optic Nerve
Biological Availability
sodium-translocating ATPase
Brain
Pharmaceutical Preparations

Keywords

  • Alloxan-induced diabetic neuropathy
  • Ganglioside inner ester derivative
  • Na, K-ATPase
  • Rat vagus nerve

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K+-ATPase activity defects. / Bianchi, R.; Triban, C.; Marini, P.; Figliomeni, B.; Paro, M.; Italiano, G.; Prosdocimi, M.; Fiori, M. G.

In: Diabetes Research and Clinical Practice, Vol. 12, No. 2, 1991, p. 107-111.

Research output: Contribution to journalArticle

Bianchi, R. ; Triban, C. ; Marini, P. ; Figliomeni, B. ; Paro, M. ; Italiano, G. ; Prosdocimi, M. ; Fiori, M. G. / Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K+-ATPase activity defects. In: Diabetes Research and Clinical Practice. 1991 ; Vol. 12, No. 2. pp. 107-111.
@article{e8f3f7e517e7491a9da5cf23d342b452,
title = "Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K+-ATPase activity defects",
abstract = "Bovine brain gangliosides have been shown to prevent decay in Na+,K+-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K+-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39{\%} decrease in Na+,K+-ATPase activity of the vagus nerve, which was completely restored (96-97{\%} recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy.",
keywords = "Alloxan-induced diabetic neuropathy, Ganglioside inner ester derivative, Na, K-ATPase, Rat vagus nerve",
author = "R. Bianchi and C. Triban and P. Marini and B. Figliomeni and M. Paro and G. Italiano and M. Prosdocimi and Fiori, {M. G.}",
year = "1991",
doi = "10.1016/0168-8227(91)90087-T",
language = "English",
volume = "12",
pages = "107--111",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K+-ATPase activity defects

AU - Bianchi, R.

AU - Triban, C.

AU - Marini, P.

AU - Figliomeni, B.

AU - Paro, M.

AU - Italiano, G.

AU - Prosdocimi, M.

AU - Fiori, M. G.

PY - 1991

Y1 - 1991

N2 - Bovine brain gangliosides have been shown to prevent decay in Na+,K+-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K+-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39% decrease in Na+,K+-ATPase activity of the vagus nerve, which was completely restored (96-97% recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy.

AB - Bovine brain gangliosides have been shown to prevent decay in Na+,K+-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K+-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39% decrease in Na+,K+-ATPase activity of the vagus nerve, which was completely restored (96-97% recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy.

KW - Alloxan-induced diabetic neuropathy

KW - Ganglioside inner ester derivative

KW - Na, K-ATPase

KW - Rat vagus nerve

UR - http://www.scopus.com/inward/record.url?scp=0025860121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025860121&partnerID=8YFLogxK

U2 - 10.1016/0168-8227(91)90087-T

DO - 10.1016/0168-8227(91)90087-T

M3 - Article

VL - 12

SP - 107

EP - 111

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -